No­vo in­vests $6B+ to ex­pand man­u­fac­tur­ing fa­cil­i­ties as de­mand for We­govy sky­rock­ets

No­vo Nordisk is in­vest­ing more than DKK 42 bil­lion ($6 bil­lion) to ex­pand its ex­ist­ing man­u­fac­tur­ing fa­cil­i­ties in Den­mark, most­ly to in­crease its ac­tive phar­ma­ceu­ti­cal in­gre­di­ents (API) ca­pac­i­ty, the com­pa­ny an­nounced Fri­day.

The fa­cil­i­ties in Kalund­borg, Den­mark, will be able to man­u­fac­ture mul­ti­ple prod­ucts, in­clud­ing GLP-1s, to “meet fu­ture mar­ket de­mands” as the de­mand for its weight loss prod­uct, We­govy, con­tin­ues to soar. This in­vest­ment will al­so boost pack­ag­ing ca­pac­i­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER